Mesoblast Ltd Files 6-K Report

Ticker: MEOBF · Form: 6-K · Filed: Jul 10, 2024 · CIK: 1345099

Mesoblast LTD 6-K Filing Summary
FieldDetail
CompanyMesoblast LTD (MEOBF)
Form Type6-K
Filed DateJul 10, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory-filing, company-update

TL;DR

MESO filed a 6-K on 7/9/24 with the ASX, standard disclosure.

AI Summary

On July 9, 2024, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This filing is a Form 6-K report for the month of July 2024, detailing information about the company's operations and regulatory submissions.

Why It Matters

This filing provides an update on Mesoblast Limited's corporate activities and regulatory disclosures to the SEC, which can impact investor understanding of the company's status.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of a press release and does not contain significant new financial or operational information that would immediately alter risk.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K filing is to report information that Mesoblast Limited has made or is required to make public pursuant to Australian law, including a new release announcement filed with the Australian Securities Exchange on July 9, 2024.

When was the announcement filed with the Australian Securities Exchange?

The announcement was filed with the Australian Securities Exchange on July 9, 2024.

Who is the Chief Executive Officer of Mesoblast Limited?

Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.

What is Mesoblast Limited's primary business?

Mesoblast Limited is in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code 2836.

What is the Commission File Number for Mesoblast Limited?

The Commission File Number for Mesoblast Limited is 001-37626.

Filing Stats: 213 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-07-09 19:58:03

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated July 10, 2024 INDEX TO EXHIBITS Item 99.1 Press release of Mesoblast Ltd, dated July 9, 2024 .

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing